title: Are surrogate markers adequate to assess cardiovascular disease drugs?
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. Temple@CDER.fda.gov
authors.forename: R
authors.initials: R
authors.lastname: Temple
mesh_terms: D015415:Biomarkers; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004341:Drug Evaluation; D006801:Humans; D012306:Risk; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015415:Biomarkers; D002317:Cardiovascular Agents